Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$6 Mln
P/E Ratio
--
P/B Ratio
0.19
Industry P/E
--
Debt to Equity
0
ROE
-1.01 %
ROCE
--
Div. Yield
0 %
Book Value
0.68
EPS
--
CFO
$-159.54 Mln
EBITDA
$-191.71 Mln
Net Profit
$-188.81 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Spruce Biosciences Inc (SPRB)
| -69.10 | -60.65 | -66.01 | -81.50 | -59.95 | -- | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Spruce Biosciences Inc (SPRB)
| -85.44 | 166.99 | -75.40 | -81.65 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and... reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Read more
Executive Chairman
Mr. Michael G. Grey
Executive Chairman
Mr. Michael G. Grey
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Spruce Biosciences Inc (SPRB) stood at $ 89 Mln as on 31-Mar-25
The share price of Spruce Biosciences Inc (SPRB) is $0.13 (NASDAQ) as of 25-Apr-2025 16:12 EDT. Spruce Biosciences Inc (SPRB) has given a return of -59.95% in the last 3 years.
Spruce Biosciences Inc (SPRB) has a market capitalisation of $ 6 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Spruce Biosciences Inc (SPRB) is 0.19 times as on 25-Apr-2025, a 92% discount to its peers’ median range of 2.29 times.
Since, TTM earnings of Spruce Biosciences Inc (SPRB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Spruce Biosciences Inc (SPRB) and enter the required number of quantities and click on buy to purchase the shares of Spruce Biosciences Inc (SPRB).
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
The CEO & director of Mr. Michael G. Grey. is Spruce Biosciences Inc (SPRB), and CFO & Sr. VP is Mr. Michael G. Grey.
There is no promoter pledging in Spruce Biosciences Inc (SPRB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Spruce Biosciences Inc (SPRB) | Ratios |
|---|---|
|
Return on equity(%)
|
-161.5
|
|
Operating margin(%)
|
-1142.57
|
|
Net Margin(%)
|
-1801.72
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Spruce Biosciences Inc (SPRB) was $0 Mln.
$-0.01
(
